

AMG 139 7 mg SC, HS Group (N=6)
AMG 139 21 mg SC, HS Group (N=6)
AMG 139 70 mg SC, HS Group (N=6)
AMG 139 210 mg SC, HS Group (N=6)
AMG 139 Serum Concentration (µg/mL)
100
10
1
0.1
0.01
0
12
24
36
48
60
72
84
96
108
120
132
144
156
168
180
Time (day)

Figure 1



AMG 139 210 mg IV, HS Group (N=6)
AMG 139 420 mg IV, HS Group (N=6)
AMG 139 700 mg IV, HS Group (N=6)
AMG 139 Serum Concentration (µg/mL)
1000
100
10
1
0.1
0
12
24
36
48
60
72
84
96
108
120
132
144
156
168
180
Time (day)

Figure 2



AMG 139 21 mg SC, PsO Group (N=3)
AMG 139 70 mg SC, PsO Group (N=3)
AMG 139 210 mg SC, PsO Group (N=3)
AMG 139 Serum Concentration (µg/mL)
100
10
1
0.1
0.01
0
12
24
36
48
60
72
84
96
108
120
132
144
156
168
180
Time (day)

Figure 3



AMG 139 700 mg IV, PsO Group (N=3)
AMG 139 Serum Concentration (µg/mL)
1000
100
10
1
0.1
0
12
24
36
48
60
72
84
96
108
132
156
180
204
228
Time (day)

Figure 4



Placebo Part B
Cohort B1 (21 mg SC)
Cohort B2 (70 mg SC)
Cohort B3 (210 mg SC)
Cohort B4 (700 mg IV)
Mean (+/- Standard Error) PASI Score Assessment
40
30
20
10
0
BL
15
29
43
57
85
113
169
197
225
253
Study Day

Figure 5



Mean (+/- SE) % Improvement of PASI Score from baseline
100
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
BL
15
29
43
57
85
113
169
197
225
253
Study day
Placebo Part B
Cohort B1 (21 mg SC)
Cohort B2 (70 mg SC)
Cohort B3 (210 mg SC)
Cohort B4 (700 mg IV)

Figure 6



Intravenous dose
Subcutaneous dose
k_a
Central Compartment Cp, V
k_{el}
k_{12}
k_{21}
Peripheral Compartment Vp

Figure 7



7 mg SC
21 mg SC
70 mg SC
210 mg SC
210 mg IV
420 mg IV
700 mg IV
Serum AMG 139 (µg/mL)
10^3
10^0
10^-3
0
50
100
150
Nominal Time (day)

Figure 8




Figure 9



CL (L/day)
0.10
0.15
0.20
0.25
0.30
0.35
60
70
80
90
100
Body Weight (kg)
Vc (L)
2
3
4
5
6
60
70
80
90
100
Body Weight (kg)

Figure 10

V_H1 (SEQ ID NO: 1)

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGR
CDR 1 CDR 2

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS
CDR 3

V_L1 (SEQ ID NO: 2)

QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPS
CDR 1 CDR 2

GVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL
CDR 3

Figure 11

SUBSTITUTE SHEET (RULE 26)